

FINAL

## **Blood transfusion: alternatives to blood transfusion for people having surgery – tranexamic acid**

**NICE guideline: acknowledgments**

*NICE guideline NG24*

*Authors and contributors*

*February 2026*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2026. All rights reserved. Subject to [Notice of rights](#).

# Contents

<b>1</b>	<b>Guideline developers .....</b>	<b>5</b>
1.1	Members of the NICE guideline committee.....	5
1.2	Members of the NICE Guideline Development Team .....	5
1.3	Members of the wider NICE Team .....	5
1.4	Acknowledgements .....	6

# 1 Guideline developers

## 1.1 Members of the NICE guideline committee:

Name	Role
Ian Bernstein	Chair
Martin Besser	Haematologist
Margaret Cheng	Lay member
Claire Frank	Pharmacist
Marioa Ganau	Surgeon (neurosurgery)
Mark Hills	Operating Department Practitioner
Nadia Ladak	Anaesthetist (paediatric)
Sarah Markham	Lay member
Fiona Murphy	Surgeon (paediatric)
Sandip Nandhra	Surgeon (vascular)
Kelly Nwankiti	Nurse (blood products)
Antony Palmer	Surgeon (orthopaedic)
Felicity Plat	Anaesthetist (adults)
Akshay Shah	Anaesthetist (adults)
Louise Strickland	Nurse (perioperative)
Marisa Taylor-Clarke	Surgeon (obstetrics)
Laura Warner	Surgeon (ENT)

## 1.2 Members of the NICE Guideline Development Team:

Name	Role
Alexandra Bonnon	Health Economist
Danielle Conroy	Project Manager
Kate Kelley	Associate Director
Sophia Kemmis Betty	Health Economics Adviser
Clifford Middleton	Topic Lead
Joanna Perkin	Senior Guidance Content Designer
George Wood	Senior Technical Analyst

## 1.3 Members of the wider NICE Team:

Name	Role
Phil Alderson	Consultant Clinical Adviser (QA)
Lucy Beggs	Health Economic Adviser (QA)
Chris Carmona	Technical Adviser (QA)
Laura Elliff-O'Shea	Technical Adviser (QA)
Benjamin Gregory	Business Analyst – Resource Impact
Cheryl Hookway	Implementation Support Manager
Jenny Kendrick	Senior Information Specialist
Anja McLoughlin	Media Relations Manager

Name	Role
Magdalena Watras	Pharmacist Clinical Adviser
Erin Whittingham	Public Involvement Adviser, People and Communities Involvement and Engagement Team

## 1.4 Acknowledgements:

We are greatly appreciative of Professor Alex Sutton and the contributors to the "Tranexamic acid in reducing expected blood loss in moderate to low risk surgeries: systematic review, meta-analysis and cost effectiveness analysis" study (referred to as Jaiswal, et al. 2025 in the evidence review). This study was fundamental to the development of our effectiveness review, assessing the clinical and cost-effectiveness of tranexamic acid for surgeries where there is a low risk of blood loss. A large proportion of this work was incorporated into the guideline and used to conduct additional analyses. We acknowledge the work of the original authors.